Evidence map›Paper›PMID 39124658›Full record

ArticleJournal of clinical medicine2024

Medullary Thyroid Carcinoma in Patients with Graves' Disease-A Case Series and Literature Review.

Oana Popa, Melania Balaș, Ioana Golu, Daniela Amzăr, Flore Varcuș, Mărioara Cornianu, Mihaela Iacob, Valentin-Tudor Popa, Mihaela Vlad

Abstract readCase Reports
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oana PopaCenter of Molecular Research in Nefrology and Vascular Disease, Department of Endocrinology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.ORCID 0000-0003-3883-2438
Melania BalașCenter of Molecular Research in Nefrology and Vascular Disease, Department of Endocrinology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Ioana GoluCenter of Molecular Research in Nefrology and Vascular Disease, Department of Endocrinology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Daniela AmzărCenter of Molecular Research in Nefrology and Vascular Disease, Department of Endocrinology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Flore VarcușDepartment of Surgery II, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Mărioara CornianuAnapatmol Research Center, Department of Pathology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Mihaela IacobAnapatmol Research Center, Department of Pathology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.
Valentin-Tudor PopaMorphoderm Research Center, Department of Dermatology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.ORCID 0000-0002-4453-2792
Mihaela VladCenter of Molecular Research in Nefrology and Vascular Disease, Department of Endocrinology, University of Medicine and Pharmacy "Victor Babeș" Timișoara, 300041 Timișoara, Romania.ORCID 0000-0002-0276-1650

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGraves' disease (GD) is an autoimmune disorder affecting the thyroid gland, leading to systemic manifestations such as hyperthyroidism, Graves' orbitopathy, and pretibial myxedema. Contrary to previous beliefs that hyperthyroidism protects against thyroid cancer, recent studies reveal an increased incidence of thyroid malignancies in GD patients, particularly differentiated thyroid carcinomas and, in rare cases, medullary thyroid carcinoma (MTC). CASE SERIES: This case series presents three female GD patients diagnosed with MTC, highlighting the complexities of diagnosis and management. All patients exhibited thyroid nodules with suspicious ultrasonographic features, elevated plasma calcitonin levels, and required total thyroidectomy. Histological examination confirmed MTC. DISCUSSION: These cases underscore the importance of routine calcitonin screening in GD patients with thyroid nodules to facilitate early detection and improve prognosis. Our findings suggest that while the coexistence of GD and MTC is likely incidental, vigilant monitoring and comprehensive evaluation are crucial for timely intervention.

conclusionsThis study advocates for integrating calcitonin testing into the standard diagnostic protocol for GD patients presenting with thyroid abnormalities.

Indexed as

calcitoninGraves’ diseasemedullary thyroid carcinomascreening

Identifiers

PMID39124658
PMCPMC11312762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.